Patients
prostate cancer, COVID-19 disease
DISEASE PROGRESSION, PROSTATE CANCER, PROSTATE
Overall, 217 patients were enrolled. 201 out 217 patients (92.6%) met the definition for study completion and received both tracers. The reasons for 16 patients not completing the study were: PSA not measured on first PET/CT injection (n = 10), lost to follow-up (n = 1), disease progression (n = 1), COVID-19 disease (n = 1), and imaging/ technical issues (n = 3). Patient flow diagram is presented in Fig. Patient flow diagramAmong 217 enrolled patients, 215/217 (99%) patients were randomised. Two-hundred-five out of 215 (95%) patients received at least one tracer injection (IMP or comparator) corresponding to 204 patients who received [Patient characteristics PSA: Prostate specific antigen; PCa: prostate cancer